HGF and neoplasm: Another therapeutic approach has been focusing on therapies to inhibit paracrine signalling of CAFs, for example, inhibitors of the HGF/MET signalling pathway, hedgehog, or angiotensin II receptor showed a reduction in the expression of CAFs and ECM content, thus enhancing drug delivery and inhibiting tumour growth and metastasis [279] (Figure 6).